ArticleBiomedical reports2025
Combined serum IFN-γ and IL-22 levels as predictive biomarkers for hepatocellular carcinoma risk: A clinical investigation.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is predominantly diagnosed at advanced stages due to a lack of reliable biomarkers for early detection. Consequently, identifying predictive biomarkers for HCC development in patients with chronic liver diseases holds significant potential for improving early diagnosis and clinical outcomes of this aggressive malignancy. Serum levels of immune checkpoint proteins and cytokines were quantified by ELISA in patients with chronic hepatitis B, liver cirrhosis, and HCC, with healthy subjects serving as controls. Cytokine profiles were compared between patients with HCC and without HCC using one-way ANOVA and multivariate logistic regression. The diagnostic performance of interferon (IFN)-γ, interleukin (IL)-22, and α-fetoprotein (AFP) was evaluated by receiver operating characteristic (ROC) curve analysis. The serum levels of programmed cell death protein 1 and programmed death-ligand 1 progressively increased with advancing stages of liver disease. IFN-γ emerged as a protective factor against HCC [odds ratio (OR)=0.991; 95% CI, 0.984-0.997], while IL-22 was identified as a risk factor (OR=1.020, 95% CI, 1.004-1.036). The combined evaluation of IFN-γ and IL-22 demonstrated superior diagnostic accuracy [area under the curve (AUC)=0.863; 95% CI, 0.755-0.971] compared with AFP alone (AUC=0.644; 95% CI, 0.483-0.804). The combination of IFN-γ and IL-22 exhibited enhanced diagnostic performance compared with AFP alone in predicting and detecting early-stage HCC, suggesting its potential utility as a novel biomarker panel for HCC screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.